INTRODUCTION {#S1}
============

The formation and regeneration of craniofacial bones of the mammalian skeleton requires the action of both intrinsic and extrinsic inductive factors from multiple cell types ([@R14]; [@R30]; [@R32]; [@R44]). Unlike the appendicular skeleton, intramembranous cranial bones form and are healed without a cartilaginous template, by condensations of mesenchymal progenitor cells. During development, these mesenchymal progenitor cells migrate to positions between the brain and surface ectoderm. There, the cells condense and differentiate along an osteogenic lineage that directly generates osteoid that subsequently mineralizes. As membranous bones expand, ossification proceeds in an ordered manner from the skull base toward the skull apex, with bones meeting in the organism's midline to form the cranial suture complex. Bounded by periosteum (PO) above and the outer meningeal layer below, the cranial suture mesenchyme is a reservoir of skeletal progenitor cells that maintains homeostasis of the uninjured skull or participates in healing the skull after injury ([@R39]; [@R60]). Despite the immediate anatomic proximity of the skull and nervous system, little is understood of how neuroskeletal intercommunication informs bone healing after injury.

Many of the cellular events following bone injury resemble those that occur during skeletal development. One notable difference is the sensation of acute pain, which is transmitted by afferent sensory nerves that innervate the appendicular skeleton ([@R4]; [@R8]). In this pathway, nerve growth factor (NGF) transmits nociceptive signals either by directly activating tropomyosin receptor kinase A (TrkA)^+^ sensory nerves or through indirect mechanisms, which intensify alternate nociceptive pathways ([@R38]; [@R45]). In addition to pain sensation, a large body of literature supports an evolutionarily conserved role of TrkA sensory nerves in organogenesis and tissue regeneration ([@R28]). For example, sensory or motor neurons are known to drive the subsequent assembly of vascular and tissue components that are responsible for the ability of the starfish and certain amphibians to regenerate entire appendages ([@R28]). However, the role of NGF-responsive nociceptive fibers in influencing mammalian bone tissue repair is not yet known.

In comparison with the long bones, in which nerve fiber frequency has been well defined ([@R4]; [@R16]; [@R21]; [@R34]), the nerve fibers that innervate the skull are less well understood. Skull-associated nerve fibers are found on both the endocranial and ectocranial surfaces of the calvaria ([@R1]; [@R47]) and have been studied in connection with migraine headaches ([@R27]). These nerve-enriched coverings of calvarial bone, such as dura and PO, are essential for coordinated bone repair ([@R11]; [@R31]; [@R57]). Yet, and despite the immediate anatomic proximity of the skull and nervous system, little is understood of how neuroskeletal intercommunication informs bone healing after injury.

In this study, we characterized the innervation of mouse cranial bone and examined the role of these nerves in a mouse model of bone injury. Our results reveal a neurotrophic mechanism that directs sensory nerve transit in cranial bone repair.

RESULTS {#S2}
=======

*Ngf* Expression in Cranial Suture Mesenchyme Coincides with Sensory Nerve Transit {#S3}
----------------------------------------------------------------------------------

*Ngf*-expressing cells in the uninjured skull were identified using a previously validated NGF-eGFP reporter animal ([Figures 1A](#F1){ref-type="fig"}--[1G](#F1){ref-type="fig"}) ([@R26]). NGF reporter activity was abundant in mesenchymal cells of all patent cranial sutures ([Figures 1A](#F1){ref-type="fig"}--[1C](#F1){ref-type="fig"}), but not the already fused posterofrontal suture ([Figure 1D](#F1){ref-type="fig"}). Immunocytochemistry performed on parallel sections showed that putative sutural stem cell markers were co-expressed with NGF reporter activity, such as the zinc finger transcription factor Gli1 ([Figure 1F](#F1){ref-type="fig"}) ([@R60]) and the Wnt regulatory protein Axin2 ([Figure 1G](#F1){ref-type="fig"}) ([@R39]). Within the bone, NGF-eGFP reporter activity was detected at lower levels in the overlying PO and underlying dura mater (DM) ([Figure 1E](#F1){ref-type="fig"}) but was absent in cortical osteocytes.

To identify peripheral nerves within the uninjured skull, we performed immunohistochemical staining using the pan-neuronal markers protein gene product 9.5 (PGP9.5) ([Figure 1H](#F1){ref-type="fig"}) and beta III tubulin (TUBB3) ([Figures 1I](#F1){ref-type="fig"},[1J](#F1){ref-type="fig"}, and [1M](#F1){ref-type="fig"}). In whole-mount preparations, PGP9.5^+^TUBB3^+^ nerve fibers were observed parallel to patent sagittal and coronal sutures ([Figures 1H](#F1){ref-type="fig"}--[1J](#F1){ref-type="fig"}). In the sagittal suture, the majority of the nerves were positive for CGRP ([Figure 1K](#F1){ref-type="fig"}), but a smaller proportion expressed the sympathetic nerve marker tyrosine hydroxylase (TH) ([Figure 1L](#F1){ref-type="fig"}). In general, uninjured calvarial bones showed comparatively less frequent nerve fibers at the dural and periosteal surfaces in whole-mount preparations ([Figure S1](#SD1){ref-type="supplementary-material"}). Imaging of coronal sections of the uninjured calvaria showed a clear enrichment of TUBB3^+^ nerve fibers within the patent cranial sutures ([Figure 1M](#F1){ref-type="fig"}), a pattern confirmed in sections from Thy1-YFP pan-neuronal reporter animals ([Figures 1N](#F1){ref-type="fig"}--[1P](#F1){ref-type="fig"}). Here, abundant YFP-positive nerve fibers are seen traversing or terminating within patent sagittal, coronal, and lambdoid sutures. In contrast, little or no YFP fluorescence was observed at sites of fused calvarial sutures (not shown).

*Ngf* Is Acutely Upregulated following Calvarial Bone Injury {#S4}
------------------------------------------------------------

To examine the role of skeletal sensory nerves in cranial bone repair, we first determined the temporo-spatial domains of *Ngf* expression in the NGF-eGFP reporter animal subjected to experimental injury. In this procedure a small (1.8 mm), circular, full-thickness defect was surgically created in the frontal bone, and re-ossification was followed over a 4 week period using microcomputed tomography (μCT) ([Figures 2A](#F2){ref-type="fig"}--[2E](#F2){ref-type="fig"}). Within the uninjured bone, patchy, weak NGF reporter was present within the PO and DM, but not in cortical osteocytes ([Figure 2F](#F2){ref-type="fig"}). At day 3 (d3) post-injury, the majority of cells within the fibro-inflammatory defect were NGF reporter positive, most notably adjacent to the injured bone ([Figure 2G](#F2){ref-type="fig"}). At later time points corresponding to re-ossification, the majority of eGFP reporter activity was localized to bone-lining cells along the re-growing defect edges (d7 and 14; [Figures 2H](#F2){ref-type="fig"} and [2I](#F2){ref-type="fig"}). At later times, NGF reporter activity waned but was still present in bone-lining cells (d28; [Figure 2J](#F2){ref-type="fig"}). At all time points, cortical osteocytes remained NGF reporter negative. Semiquantitative analysis of relative NGF-eGFP reporter activity showed a robust (approximately 50-fold) increase in NGF reporter activity at 3 days following injury ([Figure 2K](#F2){ref-type="fig"}). NGF reporter activity remained elevated over baseline throughout the study period but gradually waned to a value \~5.4-fold over uninjured calvaria by the d28 study endpoint ([Figure 2K](#F2){ref-type="fig"}).

Immunohistochemical staining of NGF-eGFP reporter sections was next performed to delineate Ngf-expressing cell types within the early bone defect niche ([Figures 2L](#F2){ref-type="fig"} and [2M](#F2){ref-type="fig"}). At early time points post-injury, PDGFRα (platelet-derived growth factor receptor α)^+^ mesenchymal cells showed high co-expression with eGFP reporter activity ([Figure 2L](#F2){ref-type="fig"}, d3 post-injury). In addition, F4/80^+^ macrophages also showed substantial NGF reporter activity ([Figure 2M](#F2){ref-type="fig"}, d3 post-injury). At later time points after ossification, we had observed bone-lining cells with the predominant cell type with eGFP reporter activity. To confirm this, osteocalcin (OCN) immunohistochemistry was performed and demonstrated that bone-lining OCN^+^ osteoblasts were the primary source of *Ngf* during later stages of defect repair ([Figure 2N](#F2){ref-type="fig"}, d14 shown).

Inflammatory Signals Drive *Ngf* Expression in Injured Calvaria {#S5}
---------------------------------------------------------------

A universal response to tissue injury is the induction of pro-inflammatory cytokines, which initiate key signaling cascades critical to tissue repair. To determine the possible role of inflammatory signals on *Ngf* expression in response to calvarial injury, inflammatory cytokine expression was assessed using immunohistochemistry within NGF-eGFP reporter sections. Robust immunoreactivity for both IL-1β and TNF-α corresponded to domains of NGF reporter activity at d3 post-injury ([Figures 3A](#F3){ref-type="fig"} and [3C](#F3){ref-type="fig"}, appearing yellow). At d7, less prominent immunoreactivity for IL-1β and TNF-α was observed, primarily in the non-ossified defect site ([Figures 3B](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}, appearing red), while NGF reporter activity had by this point become more restricted to bone-lining osteoblasts ([Figures 3B](#F3){ref-type="fig"} and [3D](#F3){ref-type="fig"}, appearing green). To determine whether these cytokines directly induced *Ngf* expression, mouse calvarial cells were exposed to recombinant IL-1β or TNF-α, and *Ngf* transcripts were assayed using qPCR. Both cytokines induced *Ngf* mRNA expression in a dose-dependent manner ([Figure 3E](#F3){ref-type="fig"}). Furthermore, both IL-1β and TNF-α induced eGFP reporter in mesenchymal cells isolated from a mouse carrying the NGF-eGFP reporter allele ([Figure 3F](#F3){ref-type="fig"}). These changes were associated with induction of NF-κB signaling activation among mouse calvarial cells ([Figure 3G](#F3){ref-type="fig"}).

Re-innervation of the Calvarial Bone Defect Follows Acute *Ngf* Upregulation {#S6}
----------------------------------------------------------------------------

A robust and acute rise in *Ngf* expression after calvarial injury would be expected to result in a prominent localized ingrowth of skeletal-associated nerve fibers. To test this idea, the temporo-spatial domains of calvarium-associated nerve fibers were next characterized over the same 28 day time interval after bone injury ([Figure 4](#F4){ref-type="fig"}). For this purpose, C57BL/6J wild-type mice were used, and injury sites were subjected to whole-mount immunohistochemical staining with the pan-neuronal marker TUBB3 ([Figures 4A](#F4){ref-type="fig"}--[4E](#F4){ref-type="fig"}). Whole-mount imaging of the endocranial aspect of the uninjured calvaria confirmed our prior findings, including a high density of nerve fibers running along the endocranial surface of the midline suture (denoted by an asterisk) and relatively less prominent nerve fibers forming a meshwork across the calvarial bone ([Figure 4A](#F4){ref-type="fig"}). Upon calvarial bone injury, re-innervation begins on the medial edge of the defect as soon as d3 ([Figure 4B](#F4){ref-type="fig"}), and progressive axonal ingrowth, sprouting, and ingrowth occur over the time course of calvarial repair ([Figures 4C](#F4){ref-type="fig"}--[4E](#F4){ref-type="fig"}). Coronal sections of the calvaria were then visualized by TUBB3 immunohistochemical staining in order to more precisely define the spatial relationships between nerve fibers within the injury site and the regenerating bone ([Figures 4F](#F4){ref-type="fig"}--[4I](#F4){ref-type="fig"}). A representative tile scan of the defect showed that the nerve fibers were most conspicuously the leading bone edges of the healing defect ([Figure 4F](#F4){ref-type="fig"}), which appeared in continuity with nerve fibers within the dura, PO, and adjacent patent suture. High-magnification images confirmed these findings, with prominent small-caliber dendrites wrapping along the healing bone edges ([Figures 4G](#F4){ref-type="fig"} and [4I](#F4){ref-type="fig"}) and less conspicuous nerve fibers within the defect center ([Figure 4H](#F4){ref-type="fig"}). Further confirmation of small nerve fiber sprouting along the bone defect edge was obtained using immunohistochemical stains for the pan-neuronal marker PGP9.5 ([Figure 4J](#F4){ref-type="fig"}). In orderto further typify the sprouting nerves, additional immunohistochemical stains were performed for the peptidergic fiber marker CGRP and sympathetic marker TH ([Figures 4K](#F4){ref-type="fig"} and [4L](#F4){ref-type="fig"}). Analysis of serial sections demonstrated that the majority of nerves entering into the healing bone defect were CGRP^+^ peptidergic nociceptors ([Figure 4K](#F4){ref-type="fig"}), while a smaller subset of nerve fibers represented TH^+^ sympathetic fibers ([Figure 4L](#F4){ref-type="fig"}). Nerve fibers closely associate with blood vessels during skeletal development and fracture repair ([@R33]; [@R52]). The spatial relationship between nerve fibers and blood vessels was interrogated by CD31 immunostaining of sections from Thy1-YFP pan-neuronal reporters. Both in uninjured calvaria and during defect healing, YFP^+^ nerve fibers were observed to course in parallel and close proximity to CD31^+^ vessels ([Figure S2](#SD1){ref-type="supplementary-material"}). Thus, injury-associated *Ngf* elaboration is associated by subsequent neurovascular infiltration of the injured bone, including predominantly CGRP^+^ fibers at sites of incipient bone formation.

Disruption of *Ngf* Attenuates Re-innervation and Impairs Calvarial Regeneration {#S7}
--------------------------------------------------------------------------------

We next determined the requirement for *Ngf* expression for normal calvarial bone repair. As multiple cell types showed NGF reporter activity within a defect niche, we first used a locoregional rather than tissue-specific approach for *Ngf* deletion. For this, *Ngf*^fl/fl^ animals were treated within the defect site with adenovirus encoding Cre recombinase (Ad-Cre), while control littermates received Ad-GFP as a control. Validation of recombination was performed using mT/mG animals, in which Ad-Cre demonstrated significant recombination within the defect site 2 days post-operatively ([Figure S3](#SD1){ref-type="supplementary-material"}). Healing among Ad-GFP- and Ad-Cre-treated bone defects was examined over a previously validated 4 week period ([@R59]) ([Figure 5](#F5){ref-type="fig"}). Results showed a significant reduction in calvarial defect re-ossification among Ad-Cre-treated *Ngf*^fl/fl^ bones, as visualized using a top-down view of μCT reconstruction as well as coronal cross-sectional images ([Figures 5A](#F5){ref-type="fig"} and [5B](#F5){ref-type="fig"}). μCT quantification was performed to assess bone healing using multiple metrics ([Figures 5C](#F5){ref-type="fig"}--[5G](#F5){ref-type="fig"}). The amount of regenerated bone within the defect site was quantified as bone volume (BV) ([Figure 5C](#F5){ref-type="fig"}; 31.3% reduction), fractional BV/tissue volume (TV) ([Figure 5D](#F5){ref-type="fig"}; 31.0% reduction), and bone fractional area (BFA) ([Figure 5E](#F5){ref-type="fig"}; 19.0% reduction). In agreement with these findings, a semiquantitative bone healing score showed a significant reduction among Ad-Cre-treated bone defect ([Figure 5F](#F5){ref-type="fig"}). Conversely, the mean diameter of the remaining non-ossified bone defect was significantly increased among Ad-Cre-treated samples ([Figure 5G](#F5){ref-type="fig"}; 205.9% increase in comparison with Ad-GFP control). In contrast, no change in bone parameters was observed with Ad-Cre treatment among uninjured calvarial bones within the same animal ([Figure S4](#SD1){ref-type="supplementary-material"}).

H&E staining confirmed a significant reduction in calvarial re-ossification, including a widened distance between bony fronts ([Figures 5H](#F5){ref-type="fig"} and [5I](#F5){ref-type="fig"}; black arrowheads indicate original defect). The frequency of TUBB3^+^ dendrites within the defect site of *Ngf* floxed animals was next assessed ([Figures 5J](#F5){ref-type="fig"}--[5L](#F5){ref-type="fig"}). TUBB3^+^ fibers were again noted most prominently at the healing defect edge ([Figure 5J](#F5){ref-type="fig"}). A dramatic reduction in TUBB3^+^ nerve fibers was observed among Ad-Cre-treated defects ([Figure 5K](#F5){ref-type="fig"}), which when quantified demonstrated a 41.5% reduction in mean TUBB3 immunoreactivity within the defect site ([Figure 5L](#F5){ref-type="fig"}). Vascularity within the bone injury site was next assessed among Ad-GFP- and Ad-Cre-treated animals ([Figures 5M](#F5){ref-type="fig"}--[5O](#F5){ref-type="fig"}). A reduction in CD31^+^ vascular channels was found within Ad-Cre-treated injury sites ([Figures 5M](#F5){ref-type="fig"} and [5N](#F5){ref-type="fig"}), demonstrating a 35.8% decrease in comparison with Ad-GFP control ([Figure 5O](#F5){ref-type="fig"}). OCN immunohistochemical staining was next performed and confirmed a significant reduction in OCN^+^ osteoblastic numbers with Ad-Cre treatment of *Ngf*^fl/fl^ animals ([Figures 5P](#F5){ref-type="fig"} and [5Q](#F5){ref-type="fig"}), reflecting a 42.9% reduction in OCN immunostaining ([Figure 5R](#F5){ref-type="fig"}). In sum, locoregional deletion of *Ngf* during bone repair led to significant reduction in injury-associated re-innervation, impaired revascularization, reduced total osteoblastic activity, and overall a significant delay in bone defect healing.

Expression of *Ngf* in LysM-Expressing Cells Is Necessary for Normal Calvarial Repair {#S8}
-------------------------------------------------------------------------------------

To further assess the requirement for NGF in calvarial defect repair, we sought to identify the cell type responsible for production of this neurotrophin. As reported above ([Figures 2L](#F2){ref-type="fig"} and [2M](#F2){ref-type="fig"}), NGF reporter activity was observed in both F4/80^+^ macrophages and PDGFRα^+^ stromal cells following calvarial injury. We therefore assessed the innervation and bone healing following disruption of NGF in each of these cell types. *Ngf*^fl/fl^ animals were crossed with either LysM-Cre or PDGFRα-CreER^T2^ lines to yield *Ngf*^fl/fl^;LysM-Cre (*Ngf*^LysM^) animals and *Ngf*^fl/fl^;PDGFRα-CreER^T2^ (*Ngf*^Pdgfrα^) animals. *Ngf*^fl/fl^;mT/mG (*Ngf*^fl/fl^) animals were used as controls ([Figure 6](#F6){ref-type="fig"}). Tamoxifen (TM) was given using previously validated injection schedules ([@R58]), and the same TM protocol was used across all strains to ensure direct comparability of the results. First, the spatial localization of PDGFRα and LysM reporter activity was confirmed ([Figures 6A](#F6){ref-type="fig"}--[6D](#F6){ref-type="fig"}). In uninjured bone, bone-lining cells (ecto- and endocranial) showed PDGFRα reporter activity ([Figure 6A](#F6){ref-type="fig"}, appearing red), while LysM reporter activity was present within cell more loosely affiliated with the endocranial bone surface ([Figure 6C](#F6){ref-type="fig"}, appearing red). As anticipated and at d3 post-operatively, both PDGFRα-expressing and LysM-expressing cells were abundant in the defect site ([Figures 6B](#F6){ref-type="fig"} and [6D](#F6){ref-type="fig"}). Validation for *Ngf* deletion was performed using NGF immunohistochemistry on calvarial injury sites within the *Ngf*^fl/fl^, *Ngf*^Pdgfrα^, and *Ngf*^LysM^ mice ([Figures 6E](#F6){ref-type="fig"}--[6G](#F6){ref-type="fig"}). NGF immunohistochemical staining (appearing green) was reduced across both *Ngf*^Pdgfrα^ and *Ngf*^LysM^ defect sites, in comparison with *Ngf*^fl/fl^ control defects. This was most conspicuous among *Ngf*^LysM^ defects, which showed few NGF immunoreactive cells ([Figure 6G](#F6){ref-type="fig"}). Some residual NGF immunostaining was present within *Ngf*^Pdgfrα^ defect sites, which as expected was present only in reporter-negative cells ([Figure 6F](#F6){ref-type="fig"}).

Next, the cell-specific requirements of *Ngf* in calvaria bone repair were assessed, using *Ngf*^fl/fl^, *Ngf*^Pdgfrα^, and *Ngf*^LysM^ mice. As in prior experiments, frontal bone healing was assessed over a 4 week period ([Figures 6H](#F6){ref-type="fig"}--[6O](#F6){ref-type="fig"}). Results demonstrated impaired bone healing among *Ngf*^LysM^ but not *Ngf*^Pdgfrα^ animals. μCT reconstructions and cross-sectional images demonstrated impaired re-ossification among *Ngf*^LysM^ mice only ([Figures 6H](#F6){ref-type="fig"}--[6J](#F6){ref-type="fig"}). Quantitative μCT metrics of bone healing were reduced among *Ngf*^LysM^ mice only, including BV ([Figure 6K](#F6){ref-type="fig"}; 33% reduction), BV/TV ([Figure 6L](#F6){ref-type="fig"}; 35% reduction), BFA ([Figure 6M](#F6){ref-type="fig"}; 28% reduction), and bone healing score ([Figure 6N](#F6){ref-type="fig"}). Consistent with this observation, the mean diameter of the bone defect area was significantly increased among *Ngf*^LysM^ animals ([Figure 6O](#F6){ref-type="fig"}; 39% increase). In contrast, no statistically significant differences in bone healing were observed between *Ngf*^Pdgfrα^ and *Ngf*^fl/fl^ animals.

Histologic examination by H&E staining verified a significant reduction in re-ossification of injury site among *Ngf*^LysM^ mice, as shown by enlarged distances between bony fronts ([Figures 6P](#F6){ref-type="fig"}--[6R](#F6){ref-type="fig"}; black arrowheads indicate original defect). The density of TUBB3^+^ nerve fibers within the defect site was next evaluated ([Figures 6S](#F6){ref-type="fig"}--[6V](#F6){ref-type="fig"}). Frequent TUBB3^+^ nerve fibers were again found around the healing bony fronts within *Ngf*^fl/fl^ and *Ngf*^Pdgfrα^ defects ([Figures 6S](#F6){ref-type="fig"} and [6T](#F6){ref-type="fig"}). In contrast, a marked reduction in TUBB3^+^ nerve fiber frequency was observed within *Ngf*^LysM^ mice ([Figure 6U](#F6){ref-type="fig"}). Quantification of TUBB3^+^ nerve fibers within the defect span confirmed a 93% reduction within *Ngf*^LysM^ animals ([Figure 6V](#F6){ref-type="fig"}). In sum, *Ngf* derived from LysM-expressing monocytes/macrophages is essential for bone defect re-innervation and osseous repair. In contrast, *Ngf* from PDGFRα-expressing stromal cells is dispensable for both defect innervation and bone healing.

TrkA Signaling Is Required for Normal Calvarial Regeneration {#S9}
------------------------------------------------------------

Much like the long bone ([@R8]), nerve fibers that extend from the trigeminal ganglia to innervate the calvarium are universally TrkA expressing ([@R17]). In order to inhibit TrkA, we used a previously validated chemical-genetic approach, in which TrkA signaling is acutely disrupted over a defined period of time. TrkA^F592A^ mice are homozygous for knockin alleles that encode a phenylalanine-to-alanine substitution in the protein kinase subdomain V, rendering its catalytic activity sensitive to specific inhibition by the membrane-permeable small molecule 1NMPP1 ([@R10]). Previously we have validated the temporal kinetics of 1NMPP1 inhibition in TrkA^F592A^ and verified that 1NMPP1 has no discernable direct effects on osteoblastic cells ([@R52]) or on bone repair in wild-type animals ([@R33]).

TrkA^F592A^ mice were now subjected to bone defects with or without 1NMPP1-mediated inhibition of TrkA ([Figure 7](#F7){ref-type="fig"}). Injury sites were again analyzed 4 weeks after defect creation, including analysis of innervation, vascularization, and ossification within the healing bone. μCT demonstrated a reduction in defect re-ossification among 1NMPP1-treated animals at d28 ([Figures 7A](#F7){ref-type="fig"} and [7B](#F7){ref-type="fig"}). Quantitative μCT metrics of bone formation demonstrated a significant reduction in all parameters among 1NMPP1-treated animals ([Figures 7C](#F7){ref-type="fig"}--[7G](#F7){ref-type="fig"}). This included reductions in BV([Figure 7C](#F7){ref-type="fig"}; 47.5% reduction), fractional BV ([Figure 7D](#F7){ref-type="fig"}; 47.2% reduction), BFA ([Figure 7E](#F7){ref-type="fig"}; 19.5% reduction), and semiquantitative bone healing score ([Figure 7F](#F7){ref-type="fig"}) and an increase in remaining non-ossified diameter of the defect ([Figure 7G](#F7){ref-type="fig"}; 120.7% increase in comparison with vehicle control). In contrast, μCT analysis of uninjured frontal bones was without detectable change among 1NMPP1-treated TrkA^F592A^ animals ([Figure S5](#SD1){ref-type="supplementary-material"}).

H&E staining confirmed a significant reduction in calvarial re-ossification, including a widened distance between bony fronts ([Figures 7H](#F7){ref-type="fig"} and [7I](#F7){ref-type="fig"}; arrowheads indicate original defect size). The frequency of TUBB3^+^ dendrites within the callus of control- and 1NMPP1-treated TrkA^F592A^;Thy1-YFP animals was next assessed ([Figures 7J](#F7){ref-type="fig"}--[7L](#F7){ref-type="fig"}). TUBB3^+^ nerve fibers were again noted most prominently at the healing defect edge ([Figure 7J](#F7){ref-type="fig"}). A dramatic reduction in TUBB3^+^ nerve fibers was observed among 1NMPP1-treated animals ([Figure 7K](#F7){ref-type="fig"}), which when quantified demonstrated a 71.2% reduction in mean TUBB3 immunoreactivity within the defect site ([Figure 7L](#F7){ref-type="fig"}). Vascularity within the bone injury site was next assessed among control- and 1NMPP1-treated TrkA^F592A^ animals ([Figures 7M](#F7){ref-type="fig"}--[7O](#F7){ref-type="fig"}). A reduction in CD31^+^ vascular channels was found within 1NMPP1-treated animals ([Figures 7M](#F7){ref-type="fig"} and [7N](#F7){ref-type="fig"}), demonstrating a 54.0% decrease in comparison with vehicle control ([Figure 7O](#F7){ref-type="fig"}). OCN immunohistochemical staining was next performed and confirmed a significant reduction in OCN^+^ osteoblastic numbers with 1NMPP1-treated TrkA^F592A^ animals ([Figures 7P](#F7){ref-type="fig"} and [7Q](#F7){ref-type="fig"}), reflecting a 37.2% reduction in OCN immunostaining ([Figure 7R](#F7){ref-type="fig"}). In aggregate, inhibition of TrkA catalytic activity over the time course of bone defect repair led to a significant reduction in injury-associated re-innervation, hampered revascularization, reduced total osteoblastic activity, and led to a significant delay in bone defect healing.

DISCUSSION {#S10}
==========

In this study, we used both genetic and immunocytochemical approaches to characterize the innervation of the mouse skull and to explore their role in cranial bone healing. Our results in both homeostatic and injury settings are compatible with the classic neurotropic model, in which acute NGF induction in the pre-innervated tissue directs the spatial and temporal ingrowth of nerves ([@R46]). In this regard, high basal expression of *Ngf* in patent suture mesenchyme appears to drive nerve ingrowth or promote nerve survival at the suture sites. In the case of calvarial injury, expression of *Ngf* among defect-associated monocytes/macrophages appears to be responsible for directing tissue re-innervation. Our observations are generally analogous to the sequence of events associated with sensory innervation of mouse long bones, in which induction of *Ngf* in perichondrial mesenchymal cells directs sensory nerves to regions of incipient mineralization ([@R52]).

Our finding that sensory nerve regrowth is critical for cranial bone repair is compatible conceptually with a large literature supporting the importance of sensory nerves in regeneration of lower order species. For example, the regeneration of limbs of certain starfish and amphibians, and healing of scales and barbells of fish, are all nerve-dependent processes ([@R22]; [@R29]; [@R48]). However, in contrast to the classic neurotropic model, which stipulates that *Ngf* production is highly restricted, neurotrophin production following injury is more ubiquitous because of the production by invading inflammatory cells. In this setting, defect-associated monocytes/macrophages appear to be the primary cell mediator of *Ngf*-dependent nerve regrowth. Although not specifically addressed, it is possible that *Ngf*-expressing macrophages observed in our study represent osteal macrophages or "osteomacs," which are known regulators of both membranous and endochondral bone formation ([@R3]). The distinction between NGF expression in tissue-resident and circulatory monocytes/macrophages would be an interesting avenue for future study. Our observations of macrophage-dependent sensory re-innervation have some support in models of Wallerian degeneration, in which strain-specific differences in macrophage recruitment in mice were linked to differences in sensory axon regeneration ([@R7]). In the context of the skeleton, our observations are in line with *Ngf* expression by macrophages in osteoarthritis ([@R50], [@R51]) and suggest common pathophysiologic mechanisms between sclerotic bone changes in osteoarthritis and the anabolic response to bone injury.

An important question that remains to be addressed is the downstream molecular mechanisms that mediate neuroskeletal intercommunication. In particular, the secondary messengers released by nociceptive fibers that regulate skeletal repair. In some regenerative contexts, clear nerve-derived factors have been elucidated. For example and in the salamander blastema, the anterior gradient protein family member nAG is secreted from nerve fibers and activates its receptor Prod 1 on blastemal cells during epimorphic regeneration ([@R29]). Various other candidate nerve-derived molecules have been examined in amphibian limb regeneration, including FGFs (fibroblast growth factors), BMPs (bone morphogenetic proteins), GGF (glial growth factor), and neurogelin ([@R6]; [@R12]; [@R29]; [@R37]; [@R40]). In our prior observations, activation of neurons within the long bone PO is necessary for mechanical load-induced Wnt signaling activity ([@R53]). Nevertheless, the exact physiologically important secondary signals released from peptidergic nerve fibers within a bone injury site remain unknown and are the subject of continued investigation.

Our findings raise the intriguing possibility that sensory nerve signaling might be activated to induce bone repair. The concept that nerve-derived signals could be pro-regenerative is certainly supported by studies in amphibians, in which surgical rerouting of nerve branches can prompt formation of an accessory limb ([@R35]). Delivery of recombinant *Ngf* itself, however, would represent a pain-evoking stimulus ([@R19]). Moreover, *Ngf* is susceptible to proteolytic degradation and has a short elimination half-life ([@R2]; [@R15]; [@R55]) and is likely not suitable for clinical translation. In a recent report in murine long bone fracture repair, the TrkA agonist gambogic amide (GA) was observed to speed fracture repair ([@R24]). These recent observations provide proof in principle of the pro-regenerative properties of TrkA signaling, which may be harnessed to drive re-innervation, revascularization, and ultimately repair of the mammalian skeleton. The close association of nerves and vessels observed here suggests as well that perivascular precursor cells that contribute to endochondral bone repair ([@R36]) may likewise be in close proximity to nerve fibers within healing membranous bones. Methods to induce tissue re-innervation without activating pain pathways would be essential for a logical translational approach of the present findings.

On the other hand, it is important to note that skeletal sensory nerves function in both skeletal nociception and anabolism. Consequently, any pharmacological approach to altering sensory nerve function might be expected to affect bone anabolism. This has already been observed in human patients, in whom neutralizing *Ngf* antibodies predispose to an unusually high rate of subchondral insufficiency fractures that come to clinical attention ([@R20]). Similarly, missense and nonsense mutations in *TRKA* (*NTRK1*) are the cause of CIPA (congenital insensitivity to pain with anhidrosis) syndrome ([@R23]), characterized in part by delayed fracture healing ([@R5]; [@R54]). These lines of evidence point to the interrelated nature of pain sensation and skeletal repair in human patients and the central importance of NGF-TrkA signaling in these linked processes.

STAR★METHODS {#S11}
============

RESOURCE AVAILABILITY {#S12}
---------------------

### Lead Contact {#S13}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Aaron W. James (<awjames@jhmi.edu>).

### Materials Availability {#S14}

This study did not generate new unique reagents.

### Data and Code Availability {#S15}

The published article includes all datasets generated or analyzed during this study.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S16}
--------------------------------------

### Animals {#S17}

All animals were housed and procedures performed under approval of the Animal Care and Use Committee (ACUC) of The Johns Hopkins University (MO16M226 & MO19M366). Mouse lines are summarized in [Key Resource Table](#T1){ref-type="table"}. NGF-eGFP mice were donated by the Kawaja laboratory, which express eGFP under the control of the mouse *NGF* promoter ([@R26]). Mice with floxed *Ngf* alleles were generated in the Minichiello laboratory ([@R41]). Thy1-YFP mice were used as a pan-neuronal reporter, which harbor a transgene derived from the mouse *Thy1* gene that directs expression of YFP in motor and sensory neurons ([@R13]). TrkA^F592A^ mice were donated from the Ginty laboratory, which are homozygous for a phenylalanine-to-alanine point mutation in exon 12 of the mouse *Ntrkl* gene (F592A) ([@R10]). This point mutation in TrkA^F592A^ mice renders the endogenous TrkA kinase sensitive to inhibition by the membrane-permeable small molecule 1NMPP1 ([@R10]). PDGFRα-CreER^T2^ mice were donated from the Bergles laboratory and high specificity of PDGFRα reporter activity has been previously validated ([@R25]; [@R58]). LysM-Cre mice were purchased from the Jackson Laboratory (Strain \#004781, Bar Harbor, ME). PDGFRα-CreER^T2^ mice were crossed with mT/mG strains to generate PDGFRα-CreER^T2^;mT/mG reporter animals. LysM-Cre mice were crossed with mT/mG or tdTomato strains to yield LysM-Cre;mT/mG or LysM-Cre;tdTomato mice. Mixed gender, 16 week old animals were used for all experiments unless otherwise stated. Wherever feasible, littermate analysis was performed while blinded to genotype.

In order to achieve locoregional NGF deletion within the skull, an adenovirus encoding either Cre Recombinase (Ad-Cre, 1045-HT. Vector Biosystems, Malvern, PA) or GFP (Ad-GFP, 1060-HT, Vector Biosystems) was injected percutaneously overlying the calvaria in mice with NGF floxed alleles ([@R41]). 1 × 10^9^ PFU particles were diluted in 50 μL normal saline and injected both 48 hr prior to surgery and 1 hr post-surgery. In select experiments, the spatial distribution of recombination was assessed using the same protocol of Ad-Cre injection in mT/mG animals ([@R42]).

In order to achieve cell specific deletion of *Ngf* within calvaria bones, *Ngf* floxed animals were crossed with either LysM-Cre; mT/mG or PDGFRα-CreER^T2^;mT/mG animals. After backcrossing, this yielded *Ngf*^fl/fl^;LysM-Cre;mT/mG (*Ngf*^LysM^) animals and *Ngf*^fl/fl^;PDGFRα-CreER^T2^;mT/mG (*Ngf*^Pdgfrα^) animals. Age matched *Ngf*^fl/fl^;mT/mG animals (*Ngf*^fl/fl^) were used as controls. In order to control for the potential skeletal effects of tamoxifen (TM), all genotypes were administered TM (150 mg/kg daily for 5 days, i.p.), and surgery performed after a 14 day chase period as we have previously validated in PDGFRα-CreER^T2^;mT/mG animals ([@R56]; [@R58]).

In order to achieve temporal inhibition of TrkA catalytic activity in TrkA^F592A^ animals, the small molecule 1NMPP1 was used ([@R18]) (Aurora Analytics, LLC, Baltimore, MD). Purity (99.2%) was confirmed by HPLC-UV254, and characterization by ^1^H NMR (400 MHz, DMSO-d6) was consistent with structure. Stock solution was prepared at 200 mM by dissolving 1NMPP1 in dimethyl sulfoxide (DMSO). For 1NMPP1 administration, intraperitoneal (IP) injections were performed 24 h before, 2 h before and 24 h after calvarial injury using a 5 mM solution at a dosage of 17 ug/g body weight. In all cases, DMSO containing vehicle was used for control treatment. Animals were thereafter maintained on 1NMPP1 containing drinking water (40 uM 1NMPP1 in ddH~2~O with 1% PBS-Tween 20).

METHOD DETAILS {#S18}
--------------

### Calvarial defect creation {#S19}

Calvarial defect creation was performed based on our prior methods ([@R9]; [@R59]). Before surgery, mice were given an intraperitoneal injection of analgesic (1 mg/kg buprenorphine SR). Briefly, hair overlying the calvaria was clipped, and the skin was aseptically prepared using alternating betadine and alcohol scrubs. Mice were anesthetized by isoflurane gas (1%--3% inh) for the duration of the experiment. After confirming deep anesthesia, a 1 cm sagittal incision was performed over the midline skull to expose the frontal bone. A 1.8 mm diameter, full-thickness, circular frontal bone defect was created using a micro surgical drill and a trephine drill bit. Meticulous care was taken to protect the neighboring sutures and the underlying tissues. Calvarial defect sites were irrigated with normal saline. Finally, the skin was sutured and the animal was monitored per established postoperative protocols. Skulls were harvested up to 28 d after injury.

### Histology and immunohistochemistry {#S20}

Calvaria were harvested and placed in 4% paraformaldehyde (PFA) at 4°C for 24 h. After sequential washes in PBS x 3, samples were decalcified in 14% EDTA (1:20 volume, Sigma-Aldrich) for 14 d at 4°C. Coronal sections of the calvaria were obtained using cryosections at 10 or 50 μm thickness. For cryosections, samples were cryoprotected in 30% sucrose overnight at 4°C before embedding in OCT (Tissue-Tek 4583, Torrance, CA). Coronal sections were mounted on adhesive slides (TruBond 380, Matsunami, Bellingham, WA). For immunohistochemistry, sections were washed in PBS x 3 for 10 min. When 50 μm sections were used, sections were next permeabilized with 0.5% Triton-X for 30 min. Next, 5% normal goat serum was applied for 30 min, then incubated in primary antibodies overnight at 4°C in a humidified chamber (see [Key Resource Table](#T1){ref-type="table"} and [Table S1](#SD1){ref-type="supplementary-material"} for a summary of antibodies used). The following day, slides were washed in PBS, incubated in the appropriate secondary antibody, A594-Goat Anti-Rabbit IgG or Goat Anti-Mouse IgG, for 1 h at 25°C, then mounted with DAPI mounting solution (Vectashield H-1500, Vector Laboratories, Burlingame, CA). Digital images of these sections were captured with 10-100 × objectives using upright fluorescent microscopy (Leica DM6, Leica Microsystems Inc., Buffalo Grove, IL) or confocal microscopy (Zeiss LSM780 FCS, Carl Zeiss Microscopy GmbH, Jena, Germany).

### Whole mount immunofluorescence {#S21}

In select experiments, skulls from C57BL/6J mice were used for whole mount imaging. Prior to immunostaining, the skin, muscle, and brain were carefully dissected away from the calvaria under a dissecting microscope, exposing the periosteum and dura mater. The samples were fixed in 4% PFA overnight at 4°C. Samples were then washed with sequential washes in PBS x 3, and permeabilized with 0.5% Triton X-100 at room temperature for 30 min. To block non-specific binding, samples were submerged in 1mL of 10% normal goat serum at room temperature for 30 min. The primary antibody was then applied (1 mL of anti-TUBB3 1:1500; anti-CGRP 1:200; or anti-TH 1:200) overnight at 4°C. Samples were then washed sequential washes in PBS x 3, and submerged in the appropriate secondary antibody (1 mL of A594-Goat Anti-Rabbit IgG, 1:200) for 1 hr at room temperature. Next, calvaria were washed in PBS x 3 and submerged in PBS in a black, glass bottom PELCO dish (Ted Pella, Inc, Redding, CA) for imaging. Imaging was performed using the 10x objective lens on a Zeiss LSM780 FCS, Carl Zeiss Microscopy).

### Isolation and culture of mouse calvarial cells {#S22}

Mouse calvarial cells were collected from C57BL/6J or NGF-eGFP embryos at postnatal day 1. Frontal and parietal bones were subjected to six sequential enzymatic digestions with a mixture containing 1 mg/mL collagenase type I (Worthington Biochemical Corporation, Lakewood, NJ, USA; LS004197) and 1 mg/mL collagenase type II (Worthington Biochemical Corporation; LS004177)([@R43]). Cell fractions from sequential digestions 3-5 were collected and cultured in α-MEM supplemented with 15% (vol/vol) FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin. To measure cytokine-induced NGF expression, cells were treated with recombinant IL-1β (1-50 ng/mL) or TNF-α (1-50 ng/mL) for 48 h, followed by qRT-PCR analysis.

### Ribonucleic acid isolation and quantitative real-time polymerase chain reaction {#S23}

Total RNA was extracted from the cultured cells using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. 0.8 κg of total RNA was used for reverse transcription with iScript cDNA synthesis kit (Bio-Rad) following manufacturer's instructions. Real-time PCR was performed using SYBR Green PCR Master Mix (Thermo Scientific) according to the manufacturer's protocol. Specific primers for SYBR green qPCR were verified by using Primer-BLAST from National Center for Biotechnology Information (NCBI). Standard cycling condition of amplification (primer T~m~ ≥ 60°C) was performed; UDG activation, 50°C, 2 min; then Dual-Lock™ DNA Polymerase, 95°C, 2 min; then Denature, 40 cycles of 95°C, 15 s; then Anneal / Extend, 40 cycles of 60°C, 1 min. Further, specificity of amplification for SYBRgreen-based qPCR was validated by the Melt Curve Plot of each reaction that the single peak reaction was observed. Relative gene expression was calculated using a 2-ΔΔCt method by normalization with *Gapdh*. Primer sequences are presented in [Key Resource Table](#T1){ref-type="table"}.

### Western Blot {#S24}

Mouse calvarial cells were stimulated with IL-1β (1 ng/mL) or TNF-α (25 ng/mL) and lysed in RIPA buffer (Thermo Fisher Scientific) with protease inhibitor cocktail (Cell Signaling Technologies, Danvers, MA, USA). The separation of proteins was performed using a 10% gradient SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. The blotted nitrocellulose membranes were directly blocked with a blocking buffer (5% bovine serum albumin in Tris-buffered saline (TBS) with 0.05% Tween-20 (TBST) for 1 hr and then probed with primary antibodies (see [Key Resource Table](#T1){ref-type="table"} and [Table S1](#SD1){ref-type="supplementary-material"}). After washing with TBST three times, membranes were incubated with a horseradish-peroxidase (HPR)-conjugated secondary antibody and visualized with ChemiDoc XRS+ System (Bio-rad, Hercules, CA).

QUANTIFICATION AND STATISTICAL ANALYSIS {#S25}
---------------------------------------

### MicroCT imaging and analysis {#S26}

Skulls were dissected free of skin and brain tissue and evaluated using a SkyScan1172 high-resolution microCT imaging system (Bruker, Kontich, Belgium). Scans were obtained at an image resolution of 10 μm, with the following settings: 1 mm of aluminum filter, X-ray voltage of 65 kVP, anode current of 153 μA, exposure time of 65ms, frame averaging of 5, and rotation step of 0.3 degrees. Three-dimensional images were then reconstructed from the 2D X-ray projections by implementing the Feldkamp algorithm using a commercial software package NRecon software (2.0.4.0 SkyScan). For the 3D morphometric analyses of images, CTVox and CTAn software (1.13 SkyScan) were used.

For calvarial defect analysis, a cylindrical volume of interest centered around each defect site was defined as the 1.6 mm in diameter and 1 mm in height with a threshold value of 80. Bone volume (BV) and tissue volume (TV) measurements were calculated from analyses performed for a volume of 100 slices. The amount of bone formation was analyzed and quantified using three methods. First, bone volume (BV) and fractional bone volume (bone volume/tissue volume (BV/TV)) were calculated from binary X-ray images. Second, bone fractional area (BFA) was calculated by using CTVox to create a 3D rendering of the calvarial defect in a top-down view, and then measuring pixels of bone within the defect divided by total defect area using Photoshop (Adobe, San Jose, California). Lastly, a semiquantitative bone healing score from 0 to 4 was assigned by 3 blinded observers according to previous published grading scales for calvarial defect healing ([@R49]). Briefly, the grading system was as follows: 0--no bone formation, 1--few bony spicules dispersed through defect, 2--bony bridging only at defect borders, 3--bony bridging over partial length of defect, and 4--bony bridging entire span of defect at longest point.

#### Histologic image analysis {#S27}

All images for quantification were obtained either with upright fluorescent microscopy (Leica DM6, Leica Microsystems Inc.) or confocal microscopy (Zeiss LSM780 FCS, Carl Zeiss Microscopy GmbH). NGF-eGFP reporter activity, TUBB3^+^ nerve fibers, CD31^+^ blood vessels, and OCN^+^ osteoblasts were quantified using either the magic wand tool of Photoshop CC, 2017 with a tolerance of 30 (Adobe, San Jose, CA) using five random 40x microscopical fields per sample or three-dimensional volumetric analysis of Imaris software v9.3 (Oxford Instruments, Belfast, UK) using eight serial fields per sample within the defect tissue.

#### Statistics {#S28}

Quantitative data are expressed at mean ± SD, with p \< 0.05 and p \< 0.01 considered significant. The number of samples are indicated in figure legends. A Shapiro-Wilk test for normality was performed on all datasets. Homogeneity was confirmed by a comparison of variances test. Parametric data was analyzed using an appropriate Student's t test when two groups were being compared, or a one-way ANOVA was used when more than two groups were compared, followed by a post hoc Tukey's test to compare two groups. Nonparametric data was analyzed with a Mann-Whitney U test when two groups were being compared or a Kruskal-Wallis one-way analysis when more than two groups were compared. Sample size calculations were performed for experiments presented in [Figures 5](#F5){ref-type="fig"}, [6](#F6){ref-type="fig"}, and [7](#F7){ref-type="fig"} based on an anticipated effect size of 1.75, using our previously published data in adult TrkA^F592A^ mice ([@R53]). For this scenario, with 8 replicates per group a two-sample t test would provide 80% power to detect effect sizes of at least 1.5 assuming a two-sided 0.05 level of significance.
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![*Ngf* Expression Domains and Innervation of the Uninjured Calvarium\
(A) Tile scan of the uninjured parietal bone and sagittal suture (center) in the NGF-eGFP reporter animal.\
(B--D) High-magnification images of cranial sutures within NGF-eGFP reporter animals, including (B) patent sagittal suture, (C) patent coronal suture, and (D) fused portion of posterofrontal suture.\
(E) NGF reporter activity within the intact frontal bone. PO, periosteum; DM, dura mater.\
(F and G) Immunohistochemical staining (appearing red) within the sagittal suture of NGF-eGFP reporter animals, including (F) Gli1 and (G) Axin2.\
(H) PGP9.5 whole-mount image of the patent sagittal suture. White dashed lines indicate margins of the patent suture, imaged from the endocranial aspect.\
(I and J) TUBB3 (beta III tubulin) whole-mount images of patent cranial sutures, including the (I) sagittal and (J) coronal suture. White dashed lines indicate margins of the patent suture, imaged from the endocranial aspect.\
(K and L) Immunohistochemical staining typifying nerve fibers within the sagittal suture, including (K) CGRP^+^ peptidergic fibers (appearing red) (L) and TH^+^ sympathetic fibers (appearing cyan). White dashed lines indicate margins of the patent suture, imaged from the endocranial aspect.\
(M) Tile scan of TUBB3^+^ nerve fibers in the uninjured frontal bone. TUBB3^+^ nerve fibers appear green.\
(N--P) Cross-sectional images of nerve fibers within patent cranial sutures using pan-neuronal Thy1-YFP transgenic reporter animals. Thy1-YFP reporter activity within patent cranial sutures, including (N) sagittal, (O) coronal, and (P) lambdoid sutures. Thy1-YFP reporter activity appears green.\
DAPI counterstain appears blue in all images. Representative images shown from n = 4 mice. All white scale bar, 50 μm. See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1598120-f0001){#F1}

![NGF-eGFP Reporter Activity following Calvarial Bone Injury\
NGF-eGFP reporter animals were subjected to a circular, full-thickness frontal bone defect (1.8 mm in diameter).\
(A--E) μCT reconstructions of the defect site in a top-down view (left) and coronal cross-sectional images (right) among (A) uninjured frontal bones and (B--E) d3--d28 post-injury. Margins of original defect are indicated by dashed black or red lines. Black scale bar, 500 μm; white scale bar, 200 μm.\
(F--J) Representative tile scans (left) and high-magnification images (right) of NGF-eGFP reporter activity in the calvarial defect site at serial time points, including (F) uninjured frontal bones and (G--J) d3--d28 post-injury. Reporter activity appears green, while nuclear counterstain appears blue. Uninjured control is shown for comparison. White arrowheads indicate margins of defect site. Dashed white lines indicate healing bone edge. White scale bar, 50 μm.\
(K) Quantification of relative NGF-eGFP reporter activity from d3--d28 post-injury.\
(L--N) Immunohistochemical staining (appearing red) within the defect area of NGF-eGFP reporter animals, including (L) PDGFRα (platelet-derived growth factor receptor α), d3 post-injury; (M) F4/80, d3 post-injury; and (N) osteocalcin (OCN), d14 after injury. In graphs, each dot represents a single animal; n = 3 animals per time point. White scale bar, 50 μm. Data are represented as mean ± SD.](nihms-1598120-f0002){#F2}

![Inflammatory Cytokines Induce *Ngf* Expression within Calvarial Osteoblasts\
(A and B) Immunohistochemistry for IL-1β, appearing red, on the calvarial injury site within NGF-eGFP reporter sections at (A) d3 and (B) d7 post-injury. Green arrowheads indicate bone-lining eGFP reporter activity, while red arrowheads indicate immunoreactivity within the defect site. White dashed lines indicate bone edges. Inset demonstrates immunoreactivity among uninjured calvarial bone. White scale bar, 50 μm; purple scale bar, 20 μm.\
(C and D) Immunohistochemistry for TNF-α, appearing red, on the calvarial injury site within NGF-eGFP reporter sections at (C) d3 and (D) d7 post-injury. Green arrowheads indicate bone-lining eGFP reporter activity, while red arrowheads indicate immunoreactivity within the defect site. White dashed lines indicate bone edges. Inset demonstrates immunoreactivity among uninjured calvarial bone. White scale bar, 50 μm; purple scale bar, 20 μm.\
(E) *Ngf* expression among calvarial osteoblasts 48 h after treatment with recombinant IL-1β or TNF-α, assessed using qRT-PCR.\
(F) *eGFP* expression among NGF-eGFP-derived calvarial osteoblasts 48 h after treatment with IL-1β (1 ng/mL) or TNF-α (25 ng/mL), assessed using qRT-PCR.\
(G) NF-κB signaling among calvarial osteoblasts 15--60 min after treatment with IL-1β (1 ng/mL) or TNF-α (25 ng/mL), assessed using western blot.\
All experiments were performed in triplicate. Representative histologic images are from n = 3 mice per time point. †p \< 0.05 and ††p \< 0.01 in comparison with control. Data are represented as mean ± SD.](nihms-1598120-f0003){#F3}

![Re-innervation during Calvarial Bone Defect Repair\
(A--E) Representative whole-mount tile scans (left) and high-magnification images (right) of TUBB3 (beta III tubulin)-stained calvarial defects from (B--E) d3 to d28 post-injury. (A) Uninjured control shown as a comparison. TUBB3^+^ nerve fibers appear green. Dashed white circles indicates margins of defect. White asterisks indicate midline suture. Upper right-hand inset depicts negative control without primary antibody application. White scale bar, 200 μm.\
(F--I) Tile scan image (F) and higher magnification images of TUBB3 immunohistochemical staining of nerve fibers, including (G and I) TUBB3^+^ nerves at the margins of the defect and (H) center of the defect, d14 post-injury. Asterisk in tile scan indicates the midline suture. White arrowheads indicate sites of prominent re-innervation adjacent to healing bone defect edges.\
(J--L) Immunohistochemical staining typifying nerve fibers within the calvarial defect at d14 post-injury, including (J) the pan-neuronal marker protein gene product 9.5 (PGP9.5), (K) the peptidergic fiber marker calcitonin gene-related peptide (CGRP), and (L) the sympathetic marker tyrosine hydroxylase (TH).\
Representative images are from n = 3 mice per time point. White scale bar, 50 μm. See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1598120-f0004){#F4}

![Local *Ngf* Deletion Impairs Calvarial Bone Defect Repair\
*Ngf*^fl/fl^ animals were locally injected with Ad-GFP or Ad-Cre virus, followed by creation of a 1.8 mm, circular, full-thickness frontal bone defect.\
(A and B) μCT reconstructions of the defect site in a top-down view (above) and coronal cross-sectional images (below) among *Ngf*^fl/fl^ animals locally injected with either (A) Ad-GFP or (B) Ad-Cre. Analysis performed at d28 post-injury. Margins of original defect are indicated by dashed black or red lines. Black scale bar, 500 μm; white scale bar, 200 μm.\
(C--G) μCT quantification of bone healing among Ad-GFP- and Ad-Cre-injected mice, including (C) bone volume (BV), (D) bone volume/tissue volume (BV/TV), (E) bone formation area (BFA), (F) bone healing score (score), and (G) defect diameter.\
(H and I) H&E stain of coronal cross-section of the healing defect site from (H) Ad-GFP- or (I) Ad-Cre-injected mice. Black arrowheads indicate span of initial defect. Black scale bar, 50 μm.\
(J--L) Immunohistochemical staining of TUBB3^+^ (beta III tubulin) nerve fibers at the defect edge from (J) Ad-GFP- or (K) Ad-Cre-injected mice, appearing green and (L) quantification of TUBB3 immunoreactivity within the calvarial defect. Dashed white lines indicate bone edge.\
(M--O) Immunohistochemical staining of CD31^+^ blood vessels at the defect edge from (M) Ad-GFP- or (N) Ad-Cre-injected mice, appearing red, and (O) quantification of CD31 immunoreactivity within the calvarial defect site. Dashed white lines indicate bone edge.\
(P--R) Immunohistochemical staining of OCN^+^ (osteocalcin) osteoblasts from (P) Ad-GFP- or (Q) Ad-Cre-injected mice, appearing cyan, and (R) quantification of OCN immunoreactivity within the calvarial defect site. Dashed white lines indicate bone edge. White scale bar, 50 μm.\
DAPI counterstain appears blue in all images. In graphs, each dot represents a single animal; n = 8 animals per group. †p \< 0.05 and ††p \< 0.01 in comparison with Ad-GFP control. Data are represented as mean ± SD. See also [Figures S3](#SD1){ref-type="supplementary-material"} and [S4](#SD1){ref-type="supplementary-material"}.](nihms-1598120-f0005){#F5}

![Tissue-Specific Deletion of *Ngf* in LysM-Expressing Cells but Not Pdgfrα-Expressing Cells Blunts Calvarial Bone Defect Repair\
Tissue-specific deletion of *Ngf* was performed using LysM-Cre (*Ngf*^LysM^) or Pdgfrα-CreER^T2^ lines (*Ngf*^Pdgfrα^), and bone healing was compared with Cre^−^ animals (*Ngf*^fl/fl^). Healing was assessed using a 1.8 mm, circular, full-thickness frontal bone defect.\
(A--D) Location of PDGFRα or LysM reporter activity before and after injury. (A and B) PDGFRα reporter activity (PDGFRα-CreER^T2^-mGFP, recolored red) within the uninjured frontal bone and at d3 post-injury. White scale bar, 50 μm. (C and D) LysM reporter activity (LysM-Cre-tdTomato) within the uninjured frontal bone and at d3 post-injury. White dashed lines indicate bone edges. White scale bar, 50 μm.\
(E--G) Validation of *Ngf* deletion in either PDGFRα-expressing stromal cells (*Ngf*^Pdgfrα^) or LysM-expressing monocytes/macrophages (*Ngf*^LysM^) in comparison with *Ngf*^fl/fl^ mice, d3 post-injury. NGF immunohistochemistry among (E) *Ngf*^fl/fl^ control bone defects, (F) *Ngf*^Pdgfrα^ bone defects, or (G) *Ngf*^LysM^ bone defects. NGF immunostaining appears green, while reporter activity appears red. White scale bar, 50 μm.\
(H--J) μCT reconstructions of the defect site in a top-down view (above) and coronal cross-sectional images (below) among (H) *Ngf*^fl/fl^, (I) *Ngf*^Pdgfrα^, and (J) *Ngf*^LysM^ animals. Margins of original defect are indicated by dashed black or red lines. Black scale bar, 500 μm; white scale bar, 200 μm.\
(K--O) μCT quantification of bone healing among *Ngf*^fl/fl^, *Ngf*^Pdgfrα^, and *Ngf*^LysM^ mice including (K) bone volume (BV), (L) bone volume/tissue volume (BV/TV), (M) bone formation area (BFA), (N) bone healing score (score), and (O) defect diameter.\
(P--R) H&E stain of coronal cross-section of the healing defect site from (P) *Ngf*^fl/fl^, (Q) *Ngf*^Pdgfrα^, and (R) *Ngf*^LysM^ mice. Black arrowheads indicate span of initial defect. Black scale bar, 50 μm.\
(S--V) Immunohistochemical staining of TUBB3^+^ (beta III tubulin) nerve fibers at the defect edge from (S) *Ngf*^fl/fl^, (T) *Ngf*^Pdgfrα^, and (U) *Ngf*^LysM^ mice, appearing green, and (V) quantification of TUBB3 immunoreactivity within the calvarial defect. Dashed white lines indicate bone edge. White scale bar, 50 μm.\
In graphs, each dot represents a single animal. n = 9--11 per group for (K)--(O) and N = 7 per group for (V). †p \< 0.05 and †††p \< 0.001 in comparison with *Ngf*^fl/fl^ and *Ngf*^Pdgfrα^. Data are represented as mean ± SD. See also [Figure S5](#SD1){ref-type="supplementary-material"}.](nihms-1598120-f0006){#F6}

![TrkA Inhibition Impairs Calvarial Bone Defect Repair\
TrkA^F592A^ animals were treated systemically with 1NMPP1 (or vehicle control) to temporally inhibit TrkA catalytic activity, followed by creation of a 1.8 mm, circular, full-thickness frontal bone defect.\
(A and B) μCT reconstructions of the defect site in a top-down view (above) and coronal cross-sectional images (below) among TrkA^F592A^ animals treated with (A) vehicle control or (B) 1NMPP1. Black scale bar, 500 μm; white scale bar, 200 μm. Analysis performed at d28 post-injury. Margins of original defect are indicated by dashed black or red lines.\
(C--G) μCT quantification of bone healing, among vehicle control or 1NMPP1-injected mice, including (C) bone volume (BV), (D) bone volume/tissue volume (BV/TV), (E) bone formation area (BFA), (F) bone healing score (score), and (G) defect diameter.\
(H and I) H&E stain of representative coronal cross-section of the healing defect site from (H) vehicle control and (I) 1NMPP1-injected mice. Black arrowheads indicate span of initial defect. Black scale bar, 50 μm.\
(J--L) Immunohistochemical staining of TUBB3^+^ (beta III tubulin) nerve fibers at the defect edge from (J) vehicle control and (K) 1NMPP1-injected mice, appearing green, and (L) quantification of TUBB3 immunoreactivity within the calvarial defect. Dashed white lines indicate bone edge.\
(M--O) Immunohistochemical staining of CD31^+^ blood vessels at the defect edge from (M) vehicle control and (N) 1NMPP1-injected mice, appearing red, and (O) quantification of CD31 immunoreactivity within the calvarial defect site. Dashed white lines indicate bone edge.\
(P--R) Immunohistochemical staining of OCN^+^ (osteocalcin) osteoblasts from (P) vehicle control and (Q) 1NMPP1-injected mice, appearing cyan, and (R) quantification of OCN immunoreactivity within the calvarial defect site. Dashed white lines indicate bone edge. White scale bar, 50 μm.\
DAPI counterstain appears blue in all images. In graphs, each dot represents a single animal; n = 9 per group. †p \< 0.05 and ††p \< 0.01 in comparison with vehicle control. Data are represented as mean ± SD.](nihms-1598120-f0007){#F7}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                               SOURCE                                                IDENTIFIER
  ----------------------------------------------------------------- ----------------------------------------------------- ---------------------------------------
  Antibodies                                                                                                              
  Rabbit monoclonal Anti-Axin 2                                     Abcam                                                 Cat\# ab109307; RRID:AB_10862550
  Rabbit polyclonal Anti-CD31                                       Abcam                                                 Cat\# ab28364; RRID:AB_726362
  Rat monoclonal Anti-CD45                                          BioLegend                                             Cat\# 103144; RRID:AB_2563458
  Rabbit Anti-Calcitonin Gene Related Peptide                       Sigma-Aldrich                                         Cat\# C8198; RRID:AB_259091
  Rat monoclonal Anti-F4/80                                         Abcam                                                 Cat\# ab204467; RRID:AB_2810932
  Rabbit polyclonal Anti-Human Gli1                                 Abcam                                                 Cat\# ab49314; RRID:AB_880198
  Rabbit polyclonal Anti-IL-1 beta                                  Abcam                                                 Cat\# ab9722; RRID:AB_308765
  Rabbit polyclonal Anti-NGF                                        Abcam                                                 Cat\# ab6199; RRID:AB_2152414
  Rabbit polyclonal Anti-Osteocalcin                                Abcam                                                 Cat\# ab93876; RRID:AB_10675660
  Rabbit polyclonal Anti-PDGF receptor alpha                        Abcam                                                 Cat\# ab15501; RRID:AB_301910
  Rabbit polyclonal Anti-PGP 9.5                                    Agilent Tech                                          Cat\# Z511601-2
  Rabbit polyclonal Anti-TNF alpha                                  Abcam                                                 Cat\# ab6671; RRID:AB_305641
  Rabbit polyclonal Anti-neuron specific beta III Tubulin           Abcam                                                 Cat\# ab18207; RRID:AB_444319
  Goat Anti-Mouse IgG H&L (Alexa Fluor® 647) preadsorbed antibody   Abcam                                                 Cat\# ab150119; RRID:AB_2811129
  DyLight 594 Anti-Rabbit IgG (H+L), made in goat antibody          Vector Laboratories                                   Cat\# DI-1594; RRID:AB_2336413
  Bacterial and Virus Strains                                                                                             
  Human Adenovirus Type5 (dE1/E3)                                   Vector Biosystems                                     Cat\# 1045, Ad-CMV-iCre
  Human Adenovirus Type5 (dE1/E3)                                   Vector Biosystems                                     Cat\# 1060, Ad-GFP
  Chemicals, Peptides, and Recombinant Proteins                                                                           
  Small molecule 1NMPP1                                             Aurora Analytics                                      Cat\# N 0001
  DAPI mounting solution                                            Vector Laboratories                                   Vectashield H-1500
  14% Ethylenediaminetetraacetic acid                               Sigma-Aldrich                                         Cat\# E6511
  Critical Commercial Assays                                                                                              
  NF-KappaB Pathway Sampler Kit - 1 Kit                             Cell Signaling                                        9936T
  iScript cDNA Synthesis Kit                                        Bio-Rad                                               Cat\# 1708891
  Experimental Models: Organisms/Strains                                                                                  
  Mouse: C57BL/6J                                                   The Jackson Laboratory                                Stock \#000664
  Mouse: mT/mG                                                      The Jackson Laboratory                                Stock \#007576
  Mouse: TdTomato                                                   Donated from Cao laboratory, Jackson Laboratory       Stock \#007914
  Mouse: NGF-eGFP                                                   Donated from Kawaja laboratory                        N/A
  Mouse: *Ngf*^fl/fl^                                               Donated from Minichiello laboratory                   N/A
  Mouse: Thy1-YFP                                                   The Jackson Laboratory                                Stock \#003709
  Mouse: TrkAF592A                                                  Donated from Ginty laboratory, Jackson Laboratory     Stock \#022362
  Mouse: Pdgfrα-CreERT2                                             Donated from Bergles laboratory, Jackson Laboratory   Stock \#018280
  Mouse: LysM-Cre                                                   Jackson Laboratory                                    Stock \#004781
  Oligonucleotides                                                                                                        
  Primer: *Gapdh* Forward: 5′- GAC TTC AAC AGC AAC TCC CAC --3′     Thermo Scientific                                     N/A
  Primer: *Gapdh* Reverse: 5′- TCC ACC CTG TTG CTG TA --3′          Thermo Scientific                                     N/A
  Primer: *Ngf* Forward: 5′- ACACTCTGATCACTGCGTTTTTG --3′           Thermo Scientific                                     N/A
  Primer: *Ngf* Reverse: 5′-CCTTCTGGGACATTGCTATCTGT-3′              Thermo Scientific                                     N/A
  Primer: *eGFP* Forward: 5′- CAACCACTACCTGAGCACCC --3′             Thermo Scientific                                     N/A
  Primer: *eGFP* Reverse: 5′- GTCCATGCCGAGAGTGATCC --3′             Thermo Scientific                                     N/A
  Software and Algorithms                                                                                                 
  Leica DM6                                                         Leica Microsystems Inc.                               <https://www.leica-microsystems.com/>
  Zeiss LSM780 FCS                                                  Carl Zeiss Microscopy GmbH                            <https://www.zeiss.com/>
  SkyScan1172 high-resolution microCT imaging system                Bruker                                                <https://www.bruker.com/>
  NRecon software 2.0.4.0                                           Bruker SkyScan                                        <https://www.bruker.com/>
  CTVox & CTAn software 1.13                                        Bruker SkyScan                                        <https://www.bruker.com/>
  Photoshop CC, 2017                                                Adobe                                                 <https://www.adobe.com/>
  Imaris software v9.3                                              Oxford Instruments                                    <https://www.oxinst.com/>

###### Highlights

-   Cranial sutures represent an NGF-expressing domain in which sensory nerves transit

-   Monocyte/macrophage-derived *Ngf* induces skeletal innervation and bone repair

-   Blocking NGF-TrkA signaling delays skeletal re-innervation and blunts bone repair
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